Recent genetic advances in ADHD and diagnostic and therapeutic prospects

Expert Review of Neurotherapeutics

Volumn 3, Issue 4, 2003, Pages 453-464

  Hawi, Ziarih ^a   Kirley, Aiveen ^a   Lowe, Naomi ^a   Fitzgerald, Michael ^a   Gill, Michael ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

ADHD; Animal model; Diagnostic; Dopamine; Norepinephrine; Serotonin; Therapeutic implications

Indexed keywords

5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINE OXIDASE (FLAVIN CONTAINING); ATOMOXETINE; CATECHOL METHYLTRANSFERASE; CLONIDINE; DESIPRAMINE; DOPA; DOPAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; FLUOXETINE; METHYLPHENIDATE; NORADRENALIN; NORTRIPTYLINE; RITANSERIN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN TRANSPORTER; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ATTENTION DEFICIT DISORDER; DAT1 GENE; DBH GENE; DISEASE MARKER; DOPAMINERGIC SYSTEM; DRD1 GENE; DRD2 GENE; DRD3 GENE; DRD4 GENE; DRD5 GENE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; KNOCKOUT GENE; KNOCKOUT MOUSE; MAO A GENE; MOLECULAR GENETICS; NONHUMAN; PHARMACOGENETICS; REVIEW; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; SNAP25 GENE;

EID: 0041814509     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.4.453     Document Type: Review

References (138)

1. Mannuzza S, Klein RG, Klein DF, Bessler A, Shrout P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. Am. J. Psychiatry 159(11), 1882-1888 (2002).
2. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank and psychiatric status. Arch. Gen. Psychiatry 50(7), 565-576 (1993).
3. Nada-Raja S, Langley JD, McGee R, Williams SM, Begg DJ, Reeder AI. Inattentive and hyperactive behaviors and driving offenses in adolescence. J. Am. Acad. Child Adolesc. Psychiatry 36(4), 515-522 (1997).
4. Thapar A, Holmes J, Poulton K, Harrington R. Genetic basis of attention deficit and hyperactivity. Br. J. Psychiatry 174, 105-111 (1999).
5. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder, a category or a continuum? Genetic analysis of a large-scale twin study. Am. Acad. Child Adolesc. Psychiatry 36(6), 737-744 (1997).
6. Faraone SV, Biederman J. Neurobiology of attention deficit hyperactivity disorder. Biol. Psychiatry 44(10), 951-958 (1998).
7. Kirley A, Hawi Z, Daly G et al. Dopaminergic system genes in ADHD, toward a biological hypothesis. Neuropsychopharmacology 27(4), 607-619 (2002). An important attempt to combine the available data at the molecular level with pharmacological and animal models to formulate a biological hypothesis for attention deficit hyperactivity disorder.
8. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283 (5400), 397-401 (1999).
9. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder, a review and integration. Behav. Brain Res. 94(1), 127-152 (1998).
10. Wang Y, Xu F, Gainetdinov P, Caron M. Genetic approaches to studying norepinephrin function, knockout of mouse norepinephrin transporter. Gene. Biol. Psychiatry 46, 1124-1130 (1999).
11. Aston-Jones G, Rajkowski J, Cohen J. Role of locus coeruleus in attention and behavioural flexibility. Biol. Psychiatry 46, 1309-1320 (1999).
12. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 24(1), 125-132 (2000).
13. Wong AH, Buckle CE, Van Tol HH. Polymorphisms in dopamine receptors, what do they tell us? Eur. J. Pharmacol. 410(2-3), 183-203 (2000). Useful review of the molecular structure and function of the dopaminergic system genes.
14. Biederman J, Spencer T. Attention-deficit hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46(9), 1234-1242 (1999).
15. Amara S, Kuhar M. Neurotransmitter transporters, recent progress. Ann. Rev. Neurosci. 16, 73-93 (1993).
16. Giros B, Jaber M, Jones S, Wightman RM, Caron M. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996).
17. Jaber M, Dumartin B, Sagne C et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur. J. Neurosci. 11(10), 3499-3511 (1999).
18. Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention deficit hyperactivity disorder - the spontaneously hypertensive rat. Brain Res. 676 (2), 343-351 (1995).
19. Baumeister AA, Hawkins MF. Incoherence of neuroimmaging studies of attention deficit/hyperactivity disorder. Clin. Neuropharmacol. 24, 2-10 (2001).
20. Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155, 1325-1331 (1998).
21. Seeman P, Madras BK. Antihyperactivity medication, methylphenidate and amphetamine. Mol. Psychiatry 3, 386-396 (1998).
22. Cook EH, Stein MA, Krasowski MD et al. Association of attention deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56, 993-998 (1995).
23. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry 2, 311-313 (1997).
24. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder, preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry 4, 192-196 (1999).
25. Waldman ID, Rowe DC, Abramowitz A et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children, heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63, 1767-1776 (1998).
26. Curran S, Mill J, Tahir E et al. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol. Psychiatry 6(4), 425-428 (2001).
27. Payton A, Holmes J, Barrett JH et al. Susceptibility genes for a trait measure of attention deficit hyperactivity disorder, a pilot study in a nonclinical sample of twins. Psychiatry Res. 31,105(3), 273-278 (2001).
28. Chen CK, Chen SL, Mill J et al. The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol. Psychiatry 8(4), 393-396 (2003).
29. Barr CL, Xu C, Kroft J et al. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention deficit hyperactivity disorder. Biol. Psychiatry 49(4), 333-339 (2001)
30. Asherson P, Virdee V, Curran S et al. Association study of DSM IV attention deficit hyperactivity disorder (ADHD) and monoamine pathway genes. Am. J. Med. Genet. 81, 549 (1998).
31. Palmer CG, Bailey JN, Ramsey C et al. No evidence of linkage or linkage disequilibrium between DAT1 and attention deficit hyperactivity disorder in a large sample. Psychiatr. Genet. 9(3), 157-160 (1999).
32. Holmes J, Payton A, Barrett JH et al. Family-based and case control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol. Psychiatry 5, 523-530 (2000).
33. Todd RD, Jong YJ, Lobos EA, Reich W, Heath AC, Neuman RJ. No association of the dopamine transporter gene 3′VNTR polymorphism with ADHD subtypes in a population sample of twins. Am. J. Med. Genet. 105(8), 745-748 (2001).
34. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH. Attention deficit hyperactivity disorder, a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am. J. Med. Genet. 105(5), 471-478 (2001).
35. Muglia P, Jain U, Inkster B, Kennedy JL. A quantitative trait locus analysis of the dopamine transporter gene in adults with ADHD. Neuropsychopharmacology 27 (4), 655-662 (2002).
36. Maher BS, Marazita ML, Ferrell RE, Vanyukov MM. Dopamine system genes and attention deficit hyperactivity disorder, a meta-analysis. Psychiatr. Gene 2(4), 207-215 (2002). Meta-analysis on all published data which further support the role of the dopaminergic system in predisposing attention deficit hyperactivity disorder.
37. Swanson JM, Flodman P, Kennedy J et al. Dopamine genes and ADHD. Neurosci. Biobehav. Rev. 24, 21-22 (2000).
38. Heinz A, Goldman D, Jones DW et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22(2), 133-139 (2000).
39. Krause KL, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder, effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 285, 107-110 (2000).
40. Meador-Woodruff JH, Grandy DK, Van Tol HHM, Damask SP, Little KY. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 10, 239-248 (1994).
41. Ashgari V, Sanyal S, Buchwaldt S. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
42. LaHoste GL, Swanson JM, Wigal SB et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry 1, 121-124 (1996).
43. Swanson JM, Sunohara GA, Kennedy JL. et al. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD), a family-based approach. Mol. Psychiatry 3, 38-41 (1998).
44. Smalley SL, Bailey JN, Palmer CG et al. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit. Mol. Psychiatry 3, 427-430 (1998).
45. Rowe DC, Stever C, Giendinghagen LN et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol. Psychiatry 3, 419-426 (1998).
46. Faraone SV, Biederman J, Weiffenbach B et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry 156(5), 768-770 (1999).
47. Muglia P, Jain U, Macciardi F, Kennedy JL. Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. Am. J. Med. Genet. 96, 273-277 (2000).
48. Sunohara GA, Roberts W, Malone M. Linkage of the dopamine D4 receptor gene and attendon deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 39(12), 1537-1542 (2000).
49. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ. Association and linkage of DRD4 and DRD5 with attendon deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol. Psychiatry 5(4), 396-404 (2000).
50. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH. Attention-deficit hyperactivity disorder, a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am. J. Med. Genet. 105 (5), 471-478 (2001).
51. Holmes J, Payton A, Barrett J et al. Association of DRD4 in children with ADHD and comorbid conduct problems. Am. J. Med. Genet. 114(2), 150-153 (2002).
52. Manor I, Tyano S, Eisenberg J, Bachner-Melman R, Kotler M, Ebstein RP. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Mol. Psychiatry 7(7), 790-794 (2002).
53. Mill J, Curran S, Kent L et al. Attention deficit hyperactivity disorder (ADHD) and the dopamine D4 receptor gene, evidence of association but no linkage in a UK sample. Mol. Psychiatry 6(4), 440-444 (2001).
54. Castellanos FX, Lau E, Tayebi N et al. Lack of association between a dopamine-4 receptor polymorphism and attention deficit hyperactivity disorder, genetic and brain morphometric analyses. Mol. Psychiatr. 3, 431-434 (1998).
55. Eisenberg J, Zohar A, Mei-Tal G et al. A haplotype relative risk study of the dopamine D4 receptor (DRD4) exon III repeat polymorphism and attention deficit hyperactivity disorder (ADHD). Am. J. Med. Genet. 96 (3), 258-261 (2000).
56. Hawi Z, McCarron M, Kirley A, Fitzgerald M, Gill M. No association of the dopamine DRD4 receptor with attention deficit hyperactivity disorder (ADHD) in the Irish population. Am. J. Med. Genet. 96, 268-272 (2000).
57. Kotler M, Manor I, Sever Y et al. Failure to replicate an excess of the long dopamine D4 exon III repeat polymorphism in ADHD in a family-based study. Am. J. Med. Genet. 96(3), 278-281 (2000).
58. Todd RD, Neuman RJ, Lobos EA, Jong YJ, Reich W, Heath AC. Lack of association of dopamine D4 receptor gene polymorphisms with ADHD subtypes in a population sample of twins. Am. J. Med. Genet. 105(8), 745-748 (2001).
59. Mill JS, Caspi A, McClay J et al. The dopamine D4 receptor and the hyperactivity phenotype, developmental-epidemiological study. Mol. Psychiatry 7(4), 383-391 (2002).
60. Barr CL, Feng Y, Wigg KG et al. 5'-untranslated region of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 105(1), 84-90 (2001).
61. Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the dopamine D4 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry 158(7), 1052-1057 (2001).
62. Barr CL, Wigg KG, Feng Y et al. Attention-deficit hyperactivity disorder and the gene for the dopamine D5 receptor. Mol. Psychiatry 5, 548-551 (2000).
63. Payton A, Holmes J, Barrett JH et al. Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder, a family-based study. Am. J. Med. Genet. 105(5), 464-470 (2001).
64. Thompson M, Comings DE. Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. Am. J. Med. Genet. 81(3), 241-244 (1998).
65. Barr CL, Wigg KG, Wu J et al. Linkage study of two polymorphisms at the dopamine D3 receptor gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 96, 114-117 (2000).
66. Muglia P, Jain U, Kennedy JL. A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder. Behav. Brain Res. 130(1-2), 91-95 (2000).
67. Comings DE, Comings BG, Muhleman D et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266,13, 1793-1800 (1991).
68. Dietz G, Comings D. A simple restriction endonuclease based test for the dopamine D2 receptor gene (DRD2) haplotypes, linkage disequilibrium of the haplotypes with the Taq A1 allele. Psychiatr. Genet. 7(3), 133-135 (1997).
69. Rowe DC, den Ord EJ, Stever C et al. The DRD2 Taq 1 polymorphism and symptoms of attention deficit hyperactivity disorder. Mol. Psychiatry 4(6), 580-586 (1999).
70. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH. Further evidence for the association between attention-deficit/hyperactivity disorder and the dopamine-β-hydroxylase gene. Am. J. Med. Genet. 114(2), 154-158 (2000).
71. Wigg K, Zai G, Schachar R et al. Attention deficit hyperactivity disorder and the gene for dopamine β-hydroxylase. Am. J. Psychiatry 159(6), 1046-1048 (2002).
72. Smith KM, Daly M, Fischer M et al. Association of the dopamine βhydroxylase gene with attention deficit hyperactivity disorder, genetic analysis of the Milwaukee longitudinal study. Am. J. Med. Genet. 119B(1), 77-85 (2003).
73. Wilson MC. Coloboma mouse mutant as an animal model of hyper kinesis and attention deficit hyperactivity disorder. Neurosci. Behav. Rev. 24, 51-57 (2000).
74. Barr CL, Feng Y, Wigg K et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention deficit hyperactivity disorder. Mol. Psychiatry 5, 405-409 (2000).
75. Kustanovich V, Merriman B, McGough J, McCracken JT, Smalley SL, Nelson SF. Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol. Psychiatry 8(3), 309-315 (2003).
76. Brophy K, Hawi Z, Kirley A, Fitzgerald M, Gill M. Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD), evidence of linkage and association in the Irish population. Mol. Psychiatry 7(8), 913-917 (2002).
77. Mill J, Curran S, Kent L et al. Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am. J. Med. Genet. 114(3), 269-271 (2002).
78. Eisenberg J, Mei-Tal G, Steinberg A et al. Haplotype relative risk study of catechol-o-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD), association of the high-enzyme activity Val allele with ADHD impulsive hyperactive phenotype. Am. J. Med. Gene. 88(5), 497-502 (1999).
79. Qian Q, Wang Y, Zhou R, Li J, Wang B, Glatt S, Faraone SV. Family-based and case-control association studies of catechol-o-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am. J. Med. Genet. 118B(1), 103-109 (2003).
80. Barr CL Wigg K, Malone M et al. Linkage study of and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 88(6), 710-713 (1999).
81. Hawi Z, Millar N, Daly G, Fitzgerald M, Gill M. No association between catechol-o-methyltransferase (COMT) gene polymorphism and attention deficit hyperactivity disorder (ADHD) in an Irish sample. Am. J. Med. Genet 96, 282-284 (2000).
82. Tahir E, Curran S, Yazgan Y, Ozbay F, Cirakoglu B, Asherson PJ. No association between low- and high-activity catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (adhd) in a sample of Turkish children. Am. J. Med. Genet. 96, 285-288 (2000).
83. Manor I, Kotler M, Sever Y et al. Failure to replicate an association between the catechol-o-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. Am. J. Med. Genet. 96(6), 858-860 (2000).
84. Hawi Z, Foley D, Kirley A, McCarron M, Fitzgerald M, Gill M. Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD), no evidence for association in the Irish population. Mol. Psychiatry 6(4), 420-424 (2001).
85. Jiang S, Xin R, Lin S et al. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. Am. J. Med. Gene. 105(8), 783-788 (2001).
86. 2B receptors. Int. J. Dev. Neurosci. 19(4), 365-372 (2001).
87. Tang G, Ren D, Xin R, Qian Y, Wang D, Jiang S. Lack of association between the tryptophan hydroxylase gene A218C polymorphism and attention-deficit hyperactivity disorder in Chinese Han population Am. J. Med. Gene. 105(6), 485-488 (2001).
88. Lucki I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry 44(3), 151-162 (1998).
89. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527-1531 (1996).
90. Manor I, Eisenberg J, Tyano S et al. Family-based association study of the serotonin transporter promoter region polymorphism (5-HTTLPR) in attention deficit hyperactivity disorder. Am. J. Med. Gene. 105(1), 91-95 (2001).
91. Seeger G, Schloss P, Schmidt MH. Functional polymorphism within the promoter of the serotonin transporter gene is associated with severe hyperkinetic disorder. Mol. Psychiatry 6(2), 235-238 (2001).
92. Kent L, Doerry U, Hardy E et al. A family based assertions study of three serotonin transporter polymorphism in attention deficit hyperactivity disorder (ADHD). Mol. Psychiatry 7(8), 908-912 (2002).
93. Zoroglu SS, Erdal ME, Alasehirli B et al. Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem repeat polymorphism in attention deficit hyperactivity disorder. Neuropsychobiology 45(4), 176-181 (2002).
94. 1B knockout mice. Behav. Neurosci. 113(3), 587-601 (1999).
95. Hawi Z, Dring M, Kirley A et al. Serotonergic system and attention deficit hyperactivity disorder (ADHD), a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multicentre ample. Mol. Psychiatry 7(7), 718-725 (2002). Emphasizes the importance of sample size and consequently the power to detect genes of minor or moderate effect.
96. 1B receptor gene and attention deficit hyperactivity disorder. Mol. Psychiatry 8(1), 98-102 (2003).
97. Quist JF, Barr CL, Schachar R et al. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol. Psychiatry 5(5), 537-541 (2000).
98. O'Neill MF, Hearon-Maxwell CI, Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine and MK-801 but not D1 agonist C-APB. Pharm. Biochem Behav. 63, 237-243 (1999).
99. Zoroglu SS, Erdal ME, Erdal N, Ozen S, Alasehirli B, Sivasli E. No evidence for an association between the T102c and 1438 G/A polymorphisms of the serotonin 2A receptor gene in attention deficit hyperactivity disorder in a Turkish population. Neuropsychobiology 47(1), 17-20 (2003).
100. Levitan RD, Masellis M, Basile VS et al. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. J. Affect. Disord. 71(1-3), 229-233 (2002).
101. Shih JC, Chen K, Ridd MJ. Role of MAO A and B in neurotransmitter metabolism and behaviour. Pol. J. Pharmacol. 51(1), 25-29 (1999).
102. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262, 578-580 (1993).
103. Cases O, Seif I, Grimsby J et al. Aggressive behaviour and altered amounts of brain serotonin and norepinephrin in mice lacking MAOA. Science 268, 1763-1766 (1995).
104. Jiang S, Xin R, Lin S et al. Linkage studies between ADHD and the monoamine oxidasegenes. Am. J. Med. Genet. 105, 783-788 (2001).
105. Jiang S, Xin R, Wu X et al. Association between attentiondeficit hyperactivity disorder and the DXS7 locus. Am. J. Med. Genet. 96(3), 289-292 (2000).
106. Tang G, Ren D, Xin R et al. Lack of association between the tryptophan hydroxylase gene A218C polymorphism and ADHD in Chinese Han population Am. J. Med. Genet. 105, 485-488 (2001).
107. Zimmerman H. Synatapic Transmission, Cellular and Molecular Basis. Oxford University Press, Oxford, UK (1993).
108. Aston-Jones G, Rajkowski J, Cohen J. Role of locus coeruleus in attention and behavioral flexibility. Biol. Psychiatry 46, 1309-1320 (1999).
109. Smith A, Nutt D. norepinephrin and attention lapses. Nature 380(6572), 291 (1996).
110. Arnsten A. Development of the cerebral cortex, XIV. Stress impairs prefrontal cortical function. J. Am. Acad. Child Adoles. Psychiatry 38, 220-222 (1999).
111. Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J. Pharmacol. Exp. Ther. 301(3), 1097-1102 (2002).
112. Popper CW. Pharmacological alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. (3), 605-646 (2000).
113. Biederman J, Spencer T. Attention deficit hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46(9), 1234-1242 (1999).
114. Barr CL, Kroft J, Feng Y et al. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 114(3), 255-259 (2002).
115. McEvoy B, Hawi Z, Fitzgerald M, Gill M. No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. Am. J. Med. Genet. 114(6), 665-666 (2002).
116. Comings DE, Gad-Andavolu R, Gonzalez N et al. Additive effect of three noradrenergic genes(ADRA2A, ADRA2C, DBH) on attention deficit/hyperactivity disorder and learning disabilities in Tourette Syndrome subjects. Clin. Genet. 55, 160-172 (1999).
117. Xu C, Schachar R, Tannock R et al. Linkage study of the α2A adrenergic receptor in attention-deficit hyperactivity disorder families. Am. J. Med. Genet. 105(2), 159-162 (2001).
118. Barr CL, Wigg K, Zai G et al. Attention-deficit hyperactivity disorder and the adrenergic receptors α1C and α2C. Mol. Psychiatry 6(3), 334-337 (2001).
119. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animal models of attention-deficit hyperactivity disorder. Brain Res. Rev. 42(1), 1-21 (2003).
120. Gainetdinov RR, Caron MG. An animal model of attention deficit hyperactivity disorder. Mol. Med. Today 6(1), 43-44 (2000).
121. Russell VA. The nucleus accumbens motor-limbic interface of the spontaneously hypertensive as studied in vitro by the superfusion slice technique. Neurosci. Biobehav. Rev. 24(1), 133-136 (2000).
122. Russell VA. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav. Brain Res. 130(1-2), 191-196 (2002).
123. Barkley RA. Attention Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment. Guilford, NY, USA (1990).
124. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD. Implications for research practice AND DSM-V. J. Am. Acad. Child. Adolesc. Psychiatry 36, 1065-1079 (1997).
125. Kuhne M, Schachar R, Tannack R. Impact of comorbid oppositional or conduct problems on attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 36, 1715-1725 (1997).
126. Faraone SV, Biederman J, Mennin D et al. Familial subtypes of attention deficit hyperactivity disorder, a 4-year follow-up study of children from antisocial-ADHD families. J. Child. Psychol. Psychiatry 39, 1045-1053 (1998).
127. Thapar A, Harrington R, McGuffin P. Examining the comorbidity of ADHD-related behaviours and conduct problems using a twin study design. Br. J. Psychiatry 179, 224-229 (2001).
128. Gillis JJ, Gilger JW, Penninngton BF, DeFries JC. Attention deficit disorders in reading disabled twins, evidence for a genetic etiology. J. Abn. Child. Psychol. 20, 303-315 (1992).
129. Curran S, Mill J, Sham P et al. QTL Association analysis of the DRD4 exon 3 VNTR polymorphism in a population sample of children screened with a parent rating scale for ADHD symptoms. Am. J. Med. Genet. 105, 387-393 (2001).
130. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad Child Adolesc. Psychiatry 38 (12), 1474-1477 (1999).
131. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz M. Dopamine transporter gene and response to methylphenidate in attention deficit hyperactivity disorder. Pharmacogenetics 12, 497-499 (2002).
132. Kidey A, Lowe N, Hawi Z et al. Association of the 480bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. (2003) (In Press).
133. Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI. Population genetic study of the human dopamine transporter gene (DAT1). Genet. Epidemiol. 12, 303-308 (1995).
134. Hawi Z, Lowe N, Kirley A et al. Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci. Mol. Psychiatry 8(3), 299-308 (2003).
135. Miller GM, Madras BK. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7, 44-55 (2000).
136. Daly MJ, Rioux JD, Schaffner SF et al. High resolution haplotype structure in the human genome. Nat. Genet. 29, 229-232 (2001).
137. Johnson GC, Esposito L, Barratt L et al. Haplotype tagging for tht identification of common disease gene. Nat. Genet. 29, 233-237 (2001).
138. Rioux JD, Daly MJ, Silverberg Ma et al. Genetic variation in the 5q31 cytokine gene duster onfers susceptibility to Crohn disease. Nat. Genet. 29(2), 223-228 (2001).